BioCentury | Apr 4, 2013
Distillery Therapeutics

Indication: Cancer

...steps include evaluating the oncolytic virus therapy in combination with chemotherapy in breast cancer models. Chemokine Therapeutics Corp....
BioCentury | Jan 22, 2009
Cover Story

Disrupting atherosclerosis

A team of German and U.S. researchers has designed a peptide that decreases atherosclerotic lesions in mice by disrupting interactions between two platelet-derived chemokines. 1 The findings have led to the formation of Carolus Therapeutics...
BioCentury | Nov 3, 2008
Clinical News

CTCE-9908: Final Phase I/II data

...were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Geneva. Chemokine Therapeutics Corp....
BioCentury | Oct 27, 2008
Company News

Chemokine Therapeutics cancer, hematology, cardiovascular news

...million. The company had a 2007 operating loss of US$5.1 million (see BioCentury, Sept. 29). Chemokine Therapeutics Corp....
BioCentury | Sep 29, 2008
Company News

Chemokine Therapeutics cancer news

...managing director and global head of the basic industries group for Banc of America Securities. Chemokine Therapeutics Corp....
BioCentury | Sep 4, 2008
Targets & Mechanisms

CXCR4 for CNS Infections

...II (tumor sensitization) Chemokine Therapeutics Corp. (TSX:CTI; OTCBB:CHKT) CTCE-9908 Stromal cell-derived factor-1 (SDF-1) analogA Cancer Phase I/II Chemokine Therapeutics...
BioCentury | Sep 1, 2008
Clinical News

CTCE-9908: Phase II start

...Chemokine will begin an open-label, international Phase II trial of intravenous CTCE-9908 in 132 patients. Chemokine Therapeutics Corp....
BioCentury | Aug 11, 2008
Clinical News

Chemokine Therapeutics preclinical data

...Conference on Metastasis in Vancouver. CTCE-9908 is a stromal cell-derived factor-1 ( SDF-1 ) analog. Chemokine Therapeutics Corp....
BioCentury | Jul 28, 2008
Company News

Chemokine Therapeutics board of directors update

Chemokine Therapeutics Corp. (TSX:CTI; OTCBB:CHKT), Vancouver, B.C. Business: Cancer, Hematology, Cardiovascular Appointed: Edward Taylor, VP of finance and administration and CFO at Oncothyreon Inc. , as chairman; he replaces Hassan Salari, who also resigned as CSO...
BioCentury | Jul 28, 2008
Company News

Chemokine Therapeutics management update

Chemokine Therapeutics Corp. (TSX:CTI; OTCBB:CHKT), Vancouver, B.C. Business: Cancer, Hematology, Cardiovascular Promoted: Walter Korz to president, CEO and a director from VP of drug development WIR Staff...
Items per page:
1 - 10 of 37
BioCentury | Apr 4, 2013
Distillery Therapeutics

Indication: Cancer

...steps include evaluating the oncolytic virus therapy in combination with chemotherapy in breast cancer models. Chemokine Therapeutics Corp....
BioCentury | Jan 22, 2009
Cover Story

Disrupting atherosclerosis

A team of German and U.S. researchers has designed a peptide that decreases atherosclerotic lesions in mice by disrupting interactions between two platelet-derived chemokines. 1 The findings have led to the formation of Carolus Therapeutics...
BioCentury | Nov 3, 2008
Clinical News

CTCE-9908: Final Phase I/II data

...were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Geneva. Chemokine Therapeutics Corp....
BioCentury | Oct 27, 2008
Company News

Chemokine Therapeutics cancer, hematology, cardiovascular news

...million. The company had a 2007 operating loss of US$5.1 million (see BioCentury, Sept. 29). Chemokine Therapeutics Corp....
BioCentury | Sep 29, 2008
Company News

Chemokine Therapeutics cancer news

...managing director and global head of the basic industries group for Banc of America Securities. Chemokine Therapeutics Corp....
BioCentury | Sep 4, 2008
Targets & Mechanisms

CXCR4 for CNS Infections

...II (tumor sensitization) Chemokine Therapeutics Corp. (TSX:CTI; OTCBB:CHKT) CTCE-9908 Stromal cell-derived factor-1 (SDF-1) analogA Cancer Phase I/II Chemokine Therapeutics...
BioCentury | Sep 1, 2008
Clinical News

CTCE-9908: Phase II start

...Chemokine will begin an open-label, international Phase II trial of intravenous CTCE-9908 in 132 patients. Chemokine Therapeutics Corp....
BioCentury | Aug 11, 2008
Clinical News

Chemokine Therapeutics preclinical data

...Conference on Metastasis in Vancouver. CTCE-9908 is a stromal cell-derived factor-1 ( SDF-1 ) analog. Chemokine Therapeutics Corp....
BioCentury | Jul 28, 2008
Company News

Chemokine Therapeutics board of directors update

Chemokine Therapeutics Corp. (TSX:CTI; OTCBB:CHKT), Vancouver, B.C. Business: Cancer, Hematology, Cardiovascular Appointed: Edward Taylor, VP of finance and administration and CFO at Oncothyreon Inc. , as chairman; he replaces Hassan Salari, who also resigned as CSO...
BioCentury | Jul 28, 2008
Company News

Chemokine Therapeutics management update

Chemokine Therapeutics Corp. (TSX:CTI; OTCBB:CHKT), Vancouver, B.C. Business: Cancer, Hematology, Cardiovascular Promoted: Walter Korz to president, CEO and a director from VP of drug development WIR Staff...
Items per page:
1 - 10 of 37